title: Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
authors.affiliation: Unit of Medical Oncology 2, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Del Vecchio
authors.forename: Roberta
authors.initials: R
authors.lastname: Mortarini
authors.forename: Stefania
authors.initials: S
authors.lastname: Canova
authors.forename: Lorenza
authors.initials: L
authors.lastname: Di Guardo
authors.forename: Nicola
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: Mario R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: Davide
authors.initials: D
authors.lastname: Bedognetti
authors.forename: Paola
authors.initials: P
authors.lastname: Queirolo
authors.forename: Paola
authors.initials: P
authors.lastname: Morosini
authors.forename: Tania
authors.initials: T
authors.lastname: Perrone
authors.forename: Emilio
authors.initials: E
authors.lastname: Bajetta
authors.forename: Andrea
authors.initials: A
authors.lastname: Anichini
mesh_terms: D000328:Adult; D000368:Aged; D042501:Angiogenic Proteins / Q000097:blood* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D042583:Lymphangiogenesis / Q000502:physiology; D008297:Male; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009607:Nitrosourea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism; D042582:Vascular Endothelial Growth Factor C / Q000097:blood / Q000378:metabolism; D055815:Young Adult
chemical_list: D042501:Angiogenic Proteins; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042582:Vascular Endothelial Growth Factor C; D000068258:Bevacizumab; C054368:fotemustine